bluebird bio
NEWS
Celgene and bluebird bio have inked a development and promotion deal for bb2121, bluebird’s B-cell maturation antigen (BCMA) CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).
A look at three small biotechs that big drugmakers are drooling over.
Here are five possible acquisition targets to keep an eye on.
Having a stock double in value is a good thing.
Many investors and analysts expect that the changes to the corporate tax code will lead to increased merger and acquisition activity in 2018.
Plenty of companies had interesting news to share at the J.P. Morgan Healthcare Conference in San Francisco this week, and bluebird bio received more attention than some.
As yet, the company has no products on the market, so the applications, if approved, would mark the company’s shift into a commercial company.
Juno Therapeutics is now the “cheapest” player now developing CAR-T cancer medications, an analyst said Wednesday as he downgraded rival Bluebird Bio.
bluebird bio stock has been on an upswing for most of the year, having recently taken a spike after positive news at the ASH Annual Meeting.
JOBS